List view / Grid view
In this journal, find articles discussing antimicrobial resistance, exploring why inhibiting the interaction between SARS-CoV-2 and neuropilin-1 could help combat COVID-19, as well as how CRISPR can be used to enhance productivity in cell line development. Also in this issue, features on engineering new biologic drugs and precision medicine.
Researchers have analysed 750 samples from patients with SARS-CoV-2 to discover details about its transmission and mutational properties.
This article lists three of the most recent advances in pre-clinical HIV research and vaccine development.
Scientists have shown how SARS-CoV-2 induces changes in the architecture of host cells to drive replication and made their data available to all.
A study in healthcare workers has shown that antibodies from COVID-19 infection protect individuals from reinfection for at least six months.
Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
Using atomistic simulations, a team has demonstrated how coronavirus Spike proteins move and vibrate to let the virus through cell walls.
Researchers say that the Ebselen compound can inhibit the replication of SARS-CoV-2 in the laboratory, so could combat COVID-19.
Scientists developed a new culture technique for alveolospheres which they used to study how alveolar cells respond to SARS-CoV-2 infection.
Researchers have found a compound that can prevent up-regulation of CD14, a key inflammatory protein, in cells.
UKRI will provide £4 million in funding to establish a data infrastructure for scientists in the UK to study antibodies from COVID-19 patient samples.
The candidates were screened based on their similarity to hydroxychloroquine and tested for efficacy against SARS-CoV-2 in vitro.
Researchers have found that neutralising antibodies for the TNF-alpha and IFN-gamma cytokines can prevent death from SARS-CoV-2 in mice.
Researchers have identified hepatitis C drugs that can inhibit the SARS-CoV-2 main protease, which enables the coronavirus to reproduce.
Hamster challenge study results suggests the oral COVID-19 vaccine induces a robust immune response, protecting the animals from infection.
